Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Retained Earnings (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Retained Earnings for 11 consecutive years, with -$2.6 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 428214.71% to -$2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 billion through Dec 2025, down 428214.71% year-over-year, with the annual reading at -$2.6 billion for FY2025, 428214.71% down from the prior year.
  • Retained Earnings for Q4 2025 was -$2.6 billion at Intellia Therapeutics, down from -$2.5 billion in the prior quarter.
  • The five-year high for Retained Earnings was $605000.0 in Q4 2024, with the low at -$2.6 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$891.9 million, with a median of -$515.7 million recorded in 2021.
  • The sharpest move saw Retained Earnings tumbled 611267.82% in 2022, then skyrocketed 126.79% in 2024.
  • Over 5 years, Retained Earnings stood at -$2.6 million in 2021, then tumbled by 183.47% to -$7.5 million in 2022, then soared by 69.74% to -$2.3 million in 2023, then surged by 126.79% to $605000.0 in 2024, then plummeted by 428214.71% to -$2.6 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$2.6 billion, -$2.5 billion, and -$2.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.